Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: The completion of the PRIMO-CABG II trial1,2 at a time when enrollment into the APEX AMI trial was still in progress enabled the steering committee and the trial sponsors to refine their estimates of the probability of detecting a clinically important benefit of pexelizumab on mortality. However, the reduction in sample size that occurred following their reassessment meant that the APEX AMI trial had only a 52% power to detect a 24% reduction in mortality at 30 days.
Eikelboom JW, O’Donnell M. Pexelizumab and the APEX AMI Trial—Reply. JAMA. 2007;297(17):1881-1882. doi:10.1001/jama.297.17.1881-c